India marks its fifth $1B drugmaker

Zydus Cadila has joined the $1 billion-turnover club of Indian drugmakers. It was a $400 million company just four years ago, and planned for the ascent to $1 billion. It hopes to reach $3 billion by 2015. Cadila is welcomed to the club by Cipla, Ranbaxy, GSK and Piramal Group. Story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.